References

1.
FDA approves first epoetin alfa biosimilar for the treatment of anemia [press release]. US Food and Drug Administration; May 15, 2018.
2.
Data on file. Pfizer Inc, New York, NY.
3.
RETACRIT [prescribing information]. Pfizer Inc; May 2018.
4.
US Food and Drug Administration. FDA briefing document. Oncologic Drugs Advisory Committee Meeting. BLA 125545: Epoetin Hospira, a proposed biosimilar to Epogen/Procrit (epoetin alfa). Hospira Inc., a Pfizer Company. May 25, 2017.
5.
Epogen [prescribing information]. Amgen Inc. September 2017.
6.
Procrit [prescribing information]. Janssen Products, LP. September 2017.